Interatrial Shunts: Devices, Clinical Results, and Future Prospects
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - National Institute of Health; Actelion; AstraZenca; Corvia Medical; Novartis; Pfizer
- Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Actelion; AstraZenca; Amgen; Axon Therapies; Bayer AG; Boehringer Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; Cytokinetics; Edwards Lifesciences; Imara; GSK; Intellia; Ionis; Lilly Medical; Merck/Schering Plough; MyoKardia; Novartis; Novo Nordisk; Pfizer; Prothena; Regeneron; Secretome; Rivus; Sardocor; Shifamed; United Therapeutics
- Equity/Stock(s)/Options - Gordian